Tuesday, Aug 11, 2020 | Last Update : 04:27 PM IST

140th Day Of Lockdown

Maharashtra52451335842118050 Tamil Nadu3028752446755041 Andhra Pradesh2355251456362116 Karnataka182354991263312 Delhi1461341316574131 Uttar Pradesh126722767212120 West Bengal98459671202059 Bihar8274154139450 Telangana8075157586637 Gujarat71064542382652 Assam5883842326145 Rajasthan5249738235789 Odisha4592731785321 Haryana4163534781483 Madhya Pradesh3902529020996 Kerala3433121832109 Jammu and Kashmir2489717003472 Punjab2390315319586 Jharkhand185168998177 Chhatisgarh12148880996 Uttarakhand96326134125 Goa871259575 Tripura6161417641 Puducherry5382320187 Manipur3752204411 Himachal Pradesh3371218114 Nagaland30119738 Arunachal Pradesh223115923 Chandigarh1595100425 Meghalaya11154986 Sikkim9105101 Mizoram6203230
  Science   11 Jul 2020  DGCI okays Itolizumab drug for restricted emergency use on COVID patients

DGCI okays Itolizumab drug for restricted emergency use on COVID patients

PTI
Published : Jul 11, 2020, 6:53 pm IST
Updated : Jul 11, 2020, 6:53 pm IST

Biocon, a domestic biopharmaceutical company, has been manufacturing and marketing the drug.

Representational image.
 Representational image.

New Delhi: Based on clinical trials data, India's drug regulator has approved itolizumab, used to treat skin condition psoriasis, for restricted emergency use on COVID-19 patients with moderate to severe acute respiratory distress, the Union health ministry said on Saturday.

Considering the unmet medical needs in COVID-19, Drugs Controller General of India (DCGI) Dr V G Somani had on Friday approved itolizumab injection for use in the treatment of coronavirus patients.

 

Biocon, a domestic biopharmaceutical company, has been manufacturing and marketing Itolizumab, a monoclonal antibody drug, for the treatment of patients with moderate to severe chronic plaque psoriasis since 2013 under the brand name Alzumab, the health ministry said.

"This indigenous drug has now been repurposed for COVID-19," it said in a statement.

The firm presented the phase II clinical trial results to the drug regulator which were deliberated upon by the Subject Expert Committee of the DCGI's office.

"After detailed deliberation and taking into account the recommendations of the committee, the DCGI has decided to grant permission to market the drug under restricted emergency use for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19," it said.

 

The use of the medicine is subject to some conditions including requirement of informed consent of patients, a risk management plan and usage only in hospital setup.

The average cost of treatment with this indigenous drug Itolizumab is lesser than other medicines which are part of investigational therapies indicated in the health ministry's Clinical Management Protocols for COVID-19.

Tags: coronavirus drug, coronavirus drug trial, coronavirus (covid-19), itolizumab